---
title: "If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295958013.md"
description: "Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years with an annualized return of 22.03%. An initial $1,000 investment would be worth $53,623.41 today. The company currently holds a market capitalization of $82.54 billion, highlighting the power of compounded returns."
datetime: "2026-08-14T16:15:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295958013.md)
  - [en](https://longbridge.com/en/news/295958013.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295958013.md)
generator: "portal-rs"
---

# If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.69% on an annualized basis producing an average annual return of 22.03%. Currently, Regeneron Pharmaceuticals has a market capitalization of $82.54 billion.

**Buying $1000 In REGN:** If an investor had bought $1000 of REGN stock 20 years ago, it would be worth **$53,623.41** today based on a price of $801.67 for REGN at the time of writing.

### Regeneron Pharmaceuticals’s Performance Over Last 20 Years

![comp_fig](https://imageproxy.pbkrs.com/https://cdn.benzinga.com/files/images/story/2026/08/14/3baa23fafe6c297ea27508e1096e2704.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Finally -- what’s the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

*This article was generated by Benzinga's automated content engine and reviewed by an editor.*

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296847570.md)
- [Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals (REGN)?](https://longbridge.com/en/news/296702017.md)
- [Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims](https://longbridge.com/en/news/296616209.md)
- [Regeneron podcast turns science into immersive experience](https://longbridge.com/en/news/296758441.md)
- [Vega Investment Solutions Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/296891476.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**